Fifth Third Bancorp Takes Position in Bioventus Inc. $BVS

Fifth Third Bancorp purchased a new position in Bioventus Inc. (NASDAQ:BVS) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 161,926 shares of the company’s stock, valued at approximately $1,478,000.

Other large investors have also recently made changes to their positions in the company. Marshall Wace LLP raised its stake in Bioventus by 0.4% in the 4th quarter. Marshall Wace LLP now owns 288,900 shares of the company’s stock valued at $2,149,000 after purchasing an additional 1,281 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Bioventus by 7.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,048 shares of the company’s stock worth $211,000 after purchasing an additional 1,538 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Bioventus by 16.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 13,529 shares of the company’s stock worth $101,000 after purchasing an additional 1,887 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Bioventus by 8.2% during the fourth quarter. Deutsche Bank AG now owns 25,138 shares of the company’s stock worth $187,000 after buying an additional 1,908 shares in the last quarter. Finally, Engineers Gate Manager LP grew its holdings in shares of Bioventus by 6.0% during the fourth quarter. Engineers Gate Manager LP now owns 68,889 shares of the company’s stock worth $513,000 after buying an additional 3,909 shares in the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. CJS Securities started coverage on shares of Bioventus in a research note on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price target on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Bioventus in a report on Tuesday, June 2nd. Barrington Research restated an “outperform” rating and issued a $14.00 price target on shares of Bioventus in a research report on Tuesday, June 30th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and issued a $15.00 price target on shares of Bioventus in a report on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $14.75.

Bioventus Trading Down 1.3%

Shares of BVS stock opened at $11.48 on Friday. The company has a current ratio of 1.69, a quick ratio of 1.13 and a debt-to-equity ratio of 1.08. Bioventus Inc. has a twelve month low of $5.81 and a twelve month high of $12.53. The company’s 50-day moving average price is $9.99 and its 200-day moving average price is $9.27. The stock has a market cap of $958.98 million, a price-to-earnings ratio of 28.00, a PEG ratio of 1.48 and a beta of 0.65.

Bioventus (NASDAQ:BVS) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The firm had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, equities analysts predict that Bioventus Inc. will post 0.79 earnings per share for the current year.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.